Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma.

TitleMicrosatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma.
Publication TypeJournal Article
Year of Publication2001
AuthorsKulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD
Date Published2001 Apr 15
KeywordsAdaptor Proteins, Signal Transducing, Adenocarcinoma, Adult, Aged, Barrett Esophagus, Carrier Proteins, Cohort Studies, Esophageal Neoplasms, Female, Humans, Immunohistochemistry, Loss of Heterozygosity, Male, Microsatellite Repeats, Middle Aged, MutL Protein Homolog 1, Neoplasm Proteins, Nuclear Proteins, Prevalence, Prognosis, Survival Analysis

BACKGROUND: Microsatellite instability (MSI) has been documented in malignancies associated with hereditary nonpolyposis colon carcinoma and in sporadic malignancies of the colon, stomach, and endometrium. In these malignancies, MSI is associated with defects in the DNA mismatch repair enzymes hMSH2 and hMLH1. Defects in these enzymes result in a phenotype characterized by instability of multiple microsatellite repeat sequences throughout the genome. This study sought to determine the prevalence of MSI in 80 primary Barrett esophagus-associated adenocarcinomas (BEAd) and to examine the relation of MSI with the clinical and pathologic features of the tumors.

METHODS: Eighty BEAd were evaluated for the presence of MSI by using the microsatellite markers BAT25, BAT26, D10S219, D10S541, and D10S551. These tumors also were evaluated for immunohistochemical expression of hMSH2 and hMLH1.

RESULTS: High levels of MSI were not found in any of the tumors examined. Furthermore, immunohistochemical expression of hMSH2 and hMLH1 was retained in all cases evaluated. Evidence of low level MSI was found in 16% of tumors. In none of these tumors, however, was MSI present in more than two of five loci. The presence of MSI did not correlate with patient age, tumor stage, degree of differentiation, or with patient survival.

CONCLUSIONS: High level MSI and loss of hMLH1/hMSH2 expression is uncommon in BEAd. A subset of BEAd demonstrate low level MSI. The presence of low level MSI was not associated with the clinicopathologic features of the tumors examined.

Alternate JournalCancer
PubMed ID11301392
Grant ListP30CA16058 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700